Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival.

Pigment Cell & Melanoma Research
Robert A CartlidgeMartin McMahon

Abstract

Somatic activating mutations of BRAF are the earliest and most common genetic abnormality detected in the genesis of human melanoma. However, the mechanism(s) by which activated BRAF promotes melanoma cell cycle progression and/or survival remain unclear. Here we demonstrate that expression of BIM, a pro-apoptotic member of the BCL-2 family, is inhibited by BRAF-->MEK-->ERK signaling in mouse and human melanocytes and in human melanoma cells. Trophic factor deprivation of melanocytes leads to elevated BIM expression. However, re-addition of trophic factors or activation of a conditional form of BRAF(V600E) leads to rapid inhibition of BIM expression. In both cases, inhibition of BIM expression was dependent on the activity of MEK1/2 and the proteasome. Consistent with these observations, pharmacological inhibition of BRAF(V600E) or MEK1/2 in human melanoma cells (using PLX4720 and CI-1040 respectively) led to a striking elevation of BIM expression. Re-activation of BRAF-->MEK-->ERK signaling led to phosphorylation of BIM-EL on serine 69 and its subsequent degradation. Interestingly, endogenous expression of BIM in melanoma cells was insufficient to induce apoptosis unless combined with serum deprivation. Under these circumstanc...Continue Reading

References

Sep 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·W S PearD Baltimore
Feb 28, 1998·The EMBO Journal·L O'ConnorD C Huang
Dec 1, 1998·Genes & Development·L ChinR A DePinho
Jul 8, 1999·Nature Medicine·J S Sebolt-LeopoldA R Saltiel
Apr 24, 2001·Genes & Development·A SchulzeJ Downward
Jun 18, 2002·Nature·Helen DaviesP Andrew Futreal
Jul 11, 2002·Cell Death and Differentiation·Manuela Baccarini
Nov 26, 2002·Nature Genetics·Pamela M PollockPaul S Meltzer
Jun 6, 2003·Oncogene·María S Soengas, Scott W Lowe
Jun 7, 2003·Nature Cell Biology·Lindsey A AllanPaul R Clarke
Jul 5, 2003·Nature Cell Biology·Mauricio J ReginatoJoan S Brugge
Oct 17, 2003·The Biochemical Journal·Catherine L DayMark G Hinds
Dec 17, 2003·Oncogene·Michela MaraniNicholas R Lemoine
Mar 11, 2004·The Journal of Investigative Dermatology·Hensin TsaoFrank G Haluska
Mar 24, 2004·Cell·Paul T C WanUNKNOWN Cancer Genome Project
Apr 3, 2004·Cancer Research·Claudia WellbrockRichard Marais
Apr 13, 2004·Oncogene·Xavier SaelensPeter Vandenabeele
Mar 23, 2005·Cancer Research·Arati SharmaGavin P Robertson
Jun 1, 2005·Molecular and Cellular Biology·Nicole L CollinsJoan S Brugge
Jun 11, 2005·Cell Death and Differentiation·R LeyS J Cook
Jun 16, 2005·Current Opinion in Pharmacology·Neil Thompson, John Lyons
Jan 18, 2006·Annual Review of Medicine·Paul G RichardsonKenneth C Anderson
Jan 19, 2006·The Journal of Investigative Dermatology·Vikas K GoelFrank G Haluska
Jul 5, 2006·The Journal of Biological Chemistry·Beibei CaiZhengui Xia
Feb 23, 2007·Nature·Vanessa Gray-SchopferRichard Marais
Jul 20, 2007·The Journal of Investigative Dermatology·Derek L DaiGang Li
Jul 27, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yu Fang WangPeter Hersey
Sep 21, 2007·Cell Cycle·Katherine E EwingsSimon J Cook
Dec 22, 2007·Nature Reviews. Molecular Cell Biology·Richard J Youle, Andreas Strasser
Feb 5, 2008·Oncogene·K Boisvert-Adamo, A E Aplin
Feb 22, 2008·Proceedings of the National Academy of Sciences of the United States of America·James TsaiGideon Bollag
Feb 22, 2008·Recent Patents on Anti-cancer Drug Discovery·Ramzi MohammadAnton-Scott Goustin

❮ Previous
Next ❯

Citations

Jun 25, 2009·Cancer Immunology, Immunotherapy : CII·Peter Hersey, Xu Dong Zhang
Jan 20, 2012·Cell Death & Disease·Y Shao, A E Aplin
Mar 14, 2009·Nature Genetics·David DankortMarcus Bosenberg
May 29, 2013·Nature Reviews. Clinical Oncology·Geoffrey T GibneyKeiran S M Smalley
Mar 8, 2012·Melanoma Research·Vito W RebeccaKeiran S M Smalley
Dec 14, 2011·The Cancer Journal·Keith T Flaherty
Jun 5, 2012·Genes & Development·Hensin TsaoDavid E Fisher
Jul 22, 2010·Cancer Research·Yongping Shao, Andrew E Aplin
Feb 22, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kim H T ParaisoKeiran S M Smalley
Nov 10, 2013·The Journal of Clinical Investigation·Victoria Marsh DurbanMartin McMahon
Jun 5, 2013·Journal of Translational Medicine·Paolo A AsciertoMagdalena Thurin
Jan 5, 2011·PLoS Genetics·Meera ShahZe'ev A Ronai
Aug 31, 2011·Pathology Research International·Sudeep Gaudi, Jane L Messina
Aug 12, 2009·Future Oncology·Keiran S M Smalley, Keith T Flaherty
Dec 24, 2013·European Journal of Cell Biology·Sandra-Annika QuastJürgen Eberle
Aug 12, 2014·Biochemical Pharmacology·Vito W Rebecca, Keiran S M Smalley
Apr 27, 2013·Expert Review of Anticancer Therapy·Heather M Shaw, Paul D Nathan
Oct 1, 2013·Expert Opinion on Emerging Drugs·Francesco SabbatinoCristina R Ferrone
Jun 2, 2014·Hematology/oncology Clinics of North America·Ryan J Sullivan, David E Fisher
Jan 28, 2012·Cancer Letters·Kris Nys, Patrizia Agostinis
Jul 3, 2009·The Journal of Investigative Dermatology·Keiran S M Smalley
Mar 29, 2014·Experimental Dermatology·Michael Plötz, Jürgen Eberle
Oct 24, 2009·Experimental Dermatology·Jürgen C BeckerRalph A Reisfeld
Jun 4, 2011·Biochemical Pharmacology·Inna V FedorenkoKeiran S M Smalley
Oct 25, 2016·Journal of the European Academy of Dermatology and Venereology : JEADV·T GambichlerM Sand
Apr 18, 2009·Molecular Aspects of Medicine·Tobias JungTilman Grune
Jun 28, 2016·International Journal of Cancer. Journal International Du Cancer·Russell MaxwellMichael Lim

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis